Target intelligence / Profile preview

Elongin C pseudogene 12 (ELOCP12)

Target
ELOCP12
Molecular classification
Other (Pseudogene)
01

Overview

Elongin C pseudogene 12 (ELOCP12) is classified as a **pseudogene** in the human genome, meaning it is a non-functional remnant of a gene related to the protein-coding gene elongin C (ELOC)[2]. ELOC encodes elongin C, a regulatory subunit of transcription elongation factor B (SIII), which is involved in transcriptional regulation and ubiquitination processes central to oxygen sensing and protein degradation[1][3]. However, **ELOCP12 itself does not produce a functional protein** and is not implicated in biological pathways or disease either as a direct effector or a therapeutic target[2]. **Interpretation and context:** - The canonical protein-coding gene (ELOC) is functionally important, but ELOCP12 refers to a pseudogene copy, not to an active gene product, enzyme, or receptor. - There is no evidence that ELOCP12 is involved in any disease process, targeted by drugs, or serves as a biomarker or biological effector. - The confusion often arises between the pseudogene and the canonical gene; the former (ELOCP12) is not a valid target, while the latter (ELOC) is involved in biologically significant pathways[1][2][3]. **Summary of critical points:** - **ELOCP12 is a pseudogene, not a protein, enzyme, or receptor.** - **It is not considered a therapeutic target.** - **It does not possess known molecular, biological, or disease-related functions.** - **No drugs, biomarkers, or safety issues are associated with it.**

Other names
TCEB1P12transcription elongation factor B (SIII), polypeptide 1 pseudogene 12transcription elongation factor B subunit 1 pseudogene 12ELOCP12

Beyond the preview

Go deeper on Elongin C pseudogene 12 (ELOCP12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elongin C pseudogene 12 (ELOCP12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call